The demonstration of true clinical proof-of-concept is a key value-creation step in the clinical development of a medicine.
The demonstration of our science data and our IP in non clinical proof-of-concept is a key value-creation step in the preclinical development of a medicine.
Melasma Pharmaceuticals is not aware of any groups worldwide that have developed products that resemble key aspects of the general concepts described in its patent applications. No substance protection for MIC8411 exists. Therefore, freedom to operate (FTO) for MIC8411 in the treatment of Melasma indications is given.
Melasma Pharmaceuticals is ready to sign an exclusive license agreement with big pharma to develop and commercialize the IP comprehensively.